New immune oncology drug molecules expected to result from leadXpro / InterAx partnership

Wednesday, April 18, 2018 @ 12:00 am

See the media release below on leadXpro AG and InterAx Biotech AG, joining forces to discover and optimize new drug lead molecules targeting G-protein coupled receptors.

You may also be interested in

Beware of fraudulent emails impersonating the Swiss Biotech Association

Don’t fall for fraudsters! Cyber criminals can reach you easily with today's communication means. We regularly detect fraudulent emails attempting to steal your passwords — both personal and for our systems — through phishing attacks. Smishing (SMS, text messages) or vishing (phone calls) are also a common way to retrieve information from you. With seemingly legitimate messages the criminals
October 8, 2024

Memo Therapeutics: Phase II trial results from kidney transplant recipients with virus infection

Phase II results show biopsy-proven resolution of BK polyomavirus nephropathy in kidney transplant recipients, with no safety or tolerability concerns observed. Results support progression into Phase III development with the potential to transform the treatment landscape for kidney transplant patients with BK polyomavirus infection.
July 25, 2025

Cosmo flash update: Key products shine - upgraded EBITDA target

July 24, 2025

Pharvaris: Topline data of pivotal Phase 3 for angioedema attacks treatment

Company expects to submit deucrictibant IR capsule NDA to the U.S. FDA for the on-demand treatment of HAE attacks in 1H2026
July 10, 2025

Cosmo flash update "Building health confidence"

July 8, 2025

RDP Pharma and Singapore's Experimental Drug Development Centre collaborate for inflammation-driven autoimmune diseases

RDP Pharma AG, a biotechnology company focused on next-generation protein degradation therapeutics, today announced a strategic research collaboration with the Experimental Drug Development Centre (EDDC), Singapore’s national platform for drug discovery and development, to jointly discover and develop a monovalent targeted protein degrader for anti-inflammatory therapies.
July 2, 2025